Priscilla Brastianos is an Oncology physician affiliated with Massachusetts General Hospital. OpenAlex indexes 559 publications with 22,936 citations (h-index 77); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Massachusetts General Hospital
Boston, MA 021142621
Telephone
617-724-4000Registry record last updated 15 Mar 2012.
Clinical trials
- Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Sponsor: Alliance for Clinical Trials in Oncology
- Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Sponsor: Massachusetts General Hospital
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Sponsor: Alliance for Clinical Trials in Oncology
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20252 payments
- Genentech USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
Massachusetts General Hospital
FY2026$2,082,604R01CA294793 - Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
Massachusetts General Hospital
FY2025$701,661R01CA294793 - Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
Massachusetts General Hospital
FY2024$701,408R01CA294793
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
New England Journal of Medicine
2023 - Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Nature Communications
2022
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”